THOUSAND OAKS, Calif., Aug. 13, 2024 /PRNewswire/ — Concept Matrix Solutions, Inc. (“CMS”) or the (“Company”), a privately held vertically integrated biotechnology company dedicated to developing and manufacturing innovative delivery forms in both pharmaceutical and nutraceutical spaces today announced that it has received patent issuance from the U.S. Patent Office (USPTO) regarding U.S. Patent No. 11,766,445 for its “Oral Soft Gel Capsule Containing Psychedelic Compound”. This patent marks a significant milestone in the company’s efforts to develop more effective treatments for mental health disorders and chronic pain conditions.
The newly patented soft gel capsule technology offers several advantages over traditional delivery methods which allows for improved rate and extent of absorption, and the reduced variability per dosage, potentially leading to more consistent and effective dosing. Furthermore, encapsulation process helps protect the psychedelic compound from degradation, potentially extending shelf life and maintaining potency. Soft gel capsules are easy to swallow and can be taken discreetly, improving patient compliance and comfort.
Concept Matrix Solutions, Inc. Receives Patent Approval for its Oral Soft Gel Capsule Containing Psychedelic Compound.
Rob Davidson, Chief Technology Officer at CMS, commented on the patent issuance: “This new delivery method represents a significant advancement in psychedelic medicine. By improving bioavailability and ease of use, we believe our soft gel capsules will help more patients benefit from the therapeutic potential of psychedelics.”
The development of novel dose forms for psychedelic compounds comes at a critical time, as mental health disorders and chronic pain conditions continue to affect millions of people worldwide. Recent studies have shown promising results for the use of psychedelics in treating anxiety, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and various forms of chronic pain.
Tony LaRosa, Chief Executive Officer at CMS, commented, “There is an urgent need for more effective treatments for these challenging conditions, traditional pharmaceuticals often fall short in providing long-lasting relief, and many patients struggle with side effects or develop tolerance. Our research suggests that psychedelic compounds, when properly administered, may offer a new paradigm in mental health and pain management.”
XYZ Pharmaceuticals is currently conducting clinical trials to evaluate the safety and efficacy of its psychedelic soft gel capsules for the treatment of anxiety, PTSD, OCD, and chronic pain. The company expects to release preliminary results later this year.
For more information about XYZ Pharmaceuticals and its research initiatives, please visit www.xyzpharma.com.
About XYZ Pharmaceuticals
XYZ Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for mental health disorders and chronic pain conditions. By leveraging cutting-edge research in psychedelic medicine and novel drug delivery technologies, XYZ Pharmaceuticals aims to improve patient outcomes and quality of life.
*This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected.*
an oral soft gel capsule for treatment for anxiety, wherein anxiety is associated with at least one of obsessive compulsive disorder (OCD), pain, irritability, fibromyalgia, post-traumatic stress disorder (PTSD), cluster headaches, paranoia, psychosis, anxiety, panic attacks, flashbacks, smoking addiction, alcohol addiction, and cocaine addiction.
SOURCE CONCEPT MATRIX SOLUTIONS
